PerkinElmer, Inc. (NYSE: PKI) Stock Competitors & Peer Comparison
See PKI's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PKI and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PKI | $115.24 | -0.91% | 14.5B | 41.45 | $2.78 | +0.24% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $656.58 | -2.98% | 242.8B | 28.35 | $23.16 | +0.28% |
| DHR | $215.61 | -2.53% | 151.5B | 27.01 | $7.98 | +0.70% |
| NTRA | $400.65 | -5.87% | 57.4B | -303.52 | -$1.32 | N/A |
| A | $169.33 | -1.14% | 47.8B | 29.15 | $5.81 | +0.60% |
| WAT | $436.43 | -0.84% | 42.9B | 31.90 | $13.68 | N/A |
| IQV | $259.98 | -2.30% | 42.8B | 21.45 | $12.13 | N/A |
| ILMN | $273.54 | -6.86% | 41.4B | 54.38 | $5.03 | N/A |
| IDXX | $515.41 | -2.21% | 40.7B | 36.25 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
PKI vs DHR-PB Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PKI's ROE is +0.03%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, PKI is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for PKI.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
PKI vs TMO Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, TMO has a market cap of 242.8B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while TMO trades at $656.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas TMO's P/E ratio is 28.35. In terms of profitability, PKI's ROE is +0.03%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PKI is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for PKI.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
PKI vs DHR Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, DHR has a market cap of 151.5B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while DHR trades at $215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas DHR's P/E ratio is 27.01. In terms of profitability, PKI's ROE is +0.03%, compared to DHR's ROE of +0.08%. Regarding short-term risk, PKI is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for PKI.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
PKI vs NTRA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NTRA has a market cap of 57.4B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NTRA trades at $400.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NTRA's P/E ratio is -303.52. In terms of profitability, PKI's ROE is +0.03%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, PKI is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
PKI vs A Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, A has a market cap of 47.8B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while A trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas A's P/E ratio is 29.15. In terms of profitability, PKI's ROE is +0.03%, compared to A's ROE of +0.20%. Regarding short-term risk, PKI is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for PKI.Check A's competition here
Waters Corporation (NYSE: WAT)
PKI vs WAT Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, WAT has a market cap of 42.9B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while WAT trades at $436.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas WAT's P/E ratio is 31.90. In terms of profitability, PKI's ROE is +0.03%, compared to WAT's ROE of +0.02%. Regarding short-term risk, PKI is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for PKI.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
PKI vs IQV Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while IQV trades at $259.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas IQV's P/E ratio is 21.45. In terms of profitability, PKI's ROE is +0.03%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PKI is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for PKI.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
PKI vs ILMN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ILMN has a market cap of 41.4B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ILMN trades at $273.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ILMN's P/E ratio is 54.38. In terms of profitability, PKI's ROE is +0.03%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, PKI is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
PKI vs IDXX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, IDXX has a market cap of 40.7B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while IDXX trades at $515.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas IDXX's P/E ratio is 36.25. In terms of profitability, PKI's ROE is +0.03%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, PKI is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for PKI.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
PKI vs MTD Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MTD has a market cap of 31B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MTD trades at $1,533.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MTD's P/E ratio is 35.21. In terms of profitability, PKI's ROE is +0.03%, compared to MTD's ROE of -12.00%. Regarding short-term risk, PKI is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
PKI vs LH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while LH trades at $311.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas LH's P/E ratio is 18.50. In terms of profitability, PKI's ROE is +0.03%, compared to LH's ROE of +0.12%. Regarding short-term risk, PKI is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for PKI.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
PKI vs DGX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, DGX has a market cap of 25.2B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while DGX trades at $228.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas DGX's P/E ratio is 22.53. In terms of profitability, PKI's ROE is +0.03%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PKI is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for PKI.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
PKI vs GH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas GH's P/E ratio is -48.91. In terms of profitability, PKI's ROE is +0.03%, compared to GH's ROE of +2.11%. Regarding short-term risk, PKI is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for PKI.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
PKI vs EXAS Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PKI's ROE is +0.03%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, PKI is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for PKI.Check EXAS's competition here
Revvity, Inc. (NYSE: RVTY)
PKI vs RVTY Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, RVTY has a market cap of 17.1B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while RVTY trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas RVTY's P/E ratio is 28.66. In terms of profitability, PKI's ROE is +0.03%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PKI is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for PKI.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
PKI vs ILMNV Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ILMNV's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to ILMNV's ROE of N/A. Regarding short-term risk, PKI is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for PKI.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
PKI vs MEDP Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MEDP has a market cap of 16.8B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MEDP trades at $602.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MEDP's P/E ratio is 35.34. In terms of profitability, PKI's ROE is +0.03%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, PKI is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MEDP's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
PKI vs CRL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CRL has a market cap of 14.7B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CRL trades at $304.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CRL's P/E ratio is 30.81. In terms of profitability, PKI's ROE is +0.03%, compared to CRL's ROE of -0.08%. Regarding short-term risk, PKI is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
PKI vs ICLR Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ICLR trades at $161.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ICLR's P/E ratio is 13.19. In terms of profitability, PKI's ROE is +0.03%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, PKI is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for PKI.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
PKI vs QGEN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, QGEN has a market cap of 9.4B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while QGEN trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas QGEN's P/E ratio is 18.87. In terms of profitability, PKI's ROE is +0.03%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PKI is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
PKI vs GRAL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while GRAL trades at $137.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas GRAL's P/E ratio is -14.08. In terms of profitability, PKI's ROE is +0.03%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, PKI is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for PKI.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
PKI vs RDNT Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while RDNT trades at $70.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas RDNT's P/E ratio is 152.78. In terms of profitability, PKI's ROE is +0.03%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PKI is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for PKI.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
PKI vs SHC Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while SHC trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas SHC's P/E ratio is 19.01. In terms of profitability, PKI's ROE is +0.03%, compared to SHC's ROE of +0.27%. Regarding short-term risk, PKI is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for PKI.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
PKI vs BLLN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BLLN trades at $99.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BLLN's P/E ratio is 142.72. In terms of profitability, PKI's ROE is +0.03%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, PKI is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
PKI vs SYNH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PKI's ROE is +0.03%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PKI is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for PKI.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
PKI vs VCYT Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while VCYT trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas VCYT's P/E ratio is 22.33. In terms of profitability, PKI's ROE is +0.03%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, PKI is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for PKI.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
PKI vs CDNA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CDNA trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CDNA's P/E ratio is 75.94. In terms of profitability, PKI's ROE is +0.03%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, PKI is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
PKI vs OLK Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas OLK's P/E ratio is -96.59. In terms of profitability, PKI's ROE is +0.03%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PKI is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for PKI.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
PKI vs WGS Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while WGS trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas WGS's P/E ratio is 198.67. In terms of profitability, PKI's ROE is +0.03%, compared to WGS's ROE of -0.39%. Regarding short-term risk, PKI is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for PKI.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
PKI vs PSNL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while PSNL trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas PSNL's P/E ratio is -14.71. In terms of profitability, PKI's ROE is +0.03%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, PKI is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for PKI.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
PKI vs OPK Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while OPK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas OPK's P/E ratio is -16.22. In terms of profitability, PKI's ROE is +0.03%, compared to OPK's ROE of -0.06%. Regarding short-term risk, PKI is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for PKI.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
PKI vs CSTL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CSTL trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CSTL's P/E ratio is -50.55. In terms of profitability, PKI's ROE is +0.03%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, PKI is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
PKI vs FLGT Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, FLGT has a market cap of 584.5M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while FLGT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas FLGT's P/E ratio is 2058.00. In terms of profitability, PKI's ROE is +0.03%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, PKI is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for PKI.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
PKI vs GRALV Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas GRALV's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to GRALV's ROE of N/A. Regarding short-term risk, PKI is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for PKI.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
PKI vs NEO Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NEO has a market cap of 424.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NEO trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NEO's P/E ratio is 126.96. In terms of profitability, PKI's ROE is +0.03%, compared to NEO's ROE of -0.06%. Regarding short-term risk, PKI is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
PKI vs MYGN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MYGN's P/E ratio is -32.92. In terms of profitability, PKI's ROE is +0.03%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, PKI is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
PKI vs CO Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CO's P/E ratio is 5.06. In terms of profitability, PKI's ROE is +0.03%, compared to CO's ROE of +0.11%. Regarding short-term risk, PKI is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
PKI vs FLDM Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PKI's ROE is +0.03%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, PKI is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for PKI.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
PKI vs BDSX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BDSX has a market cap of 227.6M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BDSX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BDSX's P/E ratio is -8.82. In terms of profitability, PKI's ROE is +0.03%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, PKI is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
PKI vs XGN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, XGN has a market cap of 197.9M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while XGN trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas XGN's P/E ratio is -10.11. In terms of profitability, PKI's ROE is +0.03%, compared to XGN's ROE of -1.22%. Regarding short-term risk, PKI is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
PKI vs FRNM Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, FRNM has a market cap of 133.5M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while FRNM trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas FRNM's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to FRNM's ROE of N/A. Regarding short-term risk, PKI is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for PKI.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
PKI vs GTH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas GTH's P/E ratio is -1.11. In terms of profitability, PKI's ROE is +0.03%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PKI is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for PKI.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
PKI vs GENE Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas GENE's P/E ratio is -38.25. In terms of profitability, PKI's ROE is +0.03%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PKI is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for PKI.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
PKI vs IMDX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas IMDX's P/E ratio is -2.27. In terms of profitability, PKI's ROE is +0.03%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, PKI is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for PKI.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
PKI vs SERA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas SERA's P/E ratio is -3.15. In terms of profitability, PKI's ROE is +0.03%, compared to SERA's ROE of -0.47%. Regarding short-term risk, PKI is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
PKI vs PRPO Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, PRPO has a market cap of 41.8M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while PRPO trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas PRPO's P/E ratio is -36.08. In terms of profitability, PKI's ROE is +0.03%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, PKI is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for PKI.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
PKI vs MDXH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MDXH has a market cap of 30.8M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MDXH's P/E ratio is -0.82. In terms of profitability, PKI's ROE is +0.03%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, PKI is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
PKI vs QUCY Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas QUCY's P/E ratio is -0.06. In terms of profitability, PKI's ROE is +0.03%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, PKI is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for PKI.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
PKI vs AKU Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas AKU's P/E ratio is -0.13. In terms of profitability, PKI's ROE is +0.03%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PKI is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for PKI.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
PKI vs BNR Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BNR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BNR's P/E ratio is -18.97. In terms of profitability, PKI's ROE is +0.03%, compared to BNR's ROE of -0.13%. Regarding short-term risk, PKI is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
PKI vs CEMI Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PKI's ROE is +0.03%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PKI is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for PKI.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
PKI vs ENZ Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PKI's ROE is +0.03%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, PKI is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for PKI.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
PKI vs PMD Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas PMD's P/E ratio is -5.24. In terms of profitability, PKI's ROE is +0.03%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PKI is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for PKI.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
PKI vs ME Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ME's P/E ratio is -0.03. In terms of profitability, PKI's ROE is +0.03%, compared to ME's ROE of -3.47%. Regarding short-term risk, PKI is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for PKI.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
PKI vs MYNZ Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, PKI's ROE is +0.03%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, PKI is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
PKI vs BIAFW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BIAFW has a market cap of 12.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BIAFW trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BIAFW's P/E ratio is 1.29. In terms of profitability, PKI's ROE is +0.03%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, PKI is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for PKI.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
PKI vs CHEK Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CHEK's P/E ratio is -0.43. In terms of profitability, PKI's ROE is +0.03%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PKI is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
PKI vs CNTG Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PKI's ROE is +0.03%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PKI is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for PKI.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
PKI vs ADVB Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ADVB's P/E ratio is -58.00. In terms of profitability, PKI's ROE is +0.03%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, PKI is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for PKI.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
PKI vs NDRA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NDRA's P/E ratio is -0.90. In terms of profitability, PKI's ROE is +0.03%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, PKI is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
PKI vs APDN Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas APDN's P/E ratio is -0.10. In terms of profitability, PKI's ROE is +0.03%, compared to APDN's ROE of -7.23%. Regarding short-term risk, PKI is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for PKI.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
PKI vs NVTA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PKI's ROE is +0.03%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PKI is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
PKI vs LMDXW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PKI's ROE is +0.03%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PKI is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for PKI.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
PKI vs LMDX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PKI's ROE is +0.03%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PKI is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for PKI.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
PKI vs DMTK Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PKI's ROE is +0.03%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PKI is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for PKI.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
PKI vs NOTV Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NOTV's P/E ratio is -0.03. In terms of profitability, PKI's ROE is +0.03%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, PKI is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
PKI vs ISPC Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas ISPC's P/E ratio is -0.03. In terms of profitability, PKI's ROE is +0.03%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, PKI is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for PKI.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
PKI vs BIAF Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BIAF's P/E ratio is -0.71. In terms of profitability, PKI's ROE is +0.03%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, PKI is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
PKI vs SQL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas SQL's P/E ratio is -0.40. In terms of profitability, PKI's ROE is +0.03%, compared to SQL's ROE of -30.46%. Regarding short-term risk, PKI is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for PKI.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
PKI vs AWH Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas AWH's P/E ratio is -0.09. In terms of profitability, PKI's ROE is +0.03%, compared to AWH's ROE of +1.62%. Regarding short-term risk, PKI is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for PKI.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
PKI vs HTGM Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PKI's ROE is +0.03%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PKI is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for PKI.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
PKI vs BIOC Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PKI's ROE is +0.03%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PKI is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
PKI vs SQLLW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, PKI's ROE is +0.03%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, PKI is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for PKI.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
PKI vs WGSWW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, PKI's ROE is +0.03%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, PKI is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for PKI.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
PKI vs DHR-PA Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PKI's ROE is +0.03%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, PKI is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for PKI.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
PKI vs OCDX Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PKI's ROE is +0.03%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PKI is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for PKI.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
PKI vs MEUSW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, PKI is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for PKI.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
PKI vs PRXL Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas PRXL's P/E ratio is 42.97. In terms of profitability, PKI's ROE is +0.03%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, PKI is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for PKI.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
PKI vs NDRAW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, PKI is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for PKI.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
PKI vs CHEKZ Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, PKI is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for PKI.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
PKI vs BNGOW Comparison October 2026
PerkinElmer, Inc. (NYSE: PKI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PKI stands at 14.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PKI is priced at $115.24 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PKI currently has a P/E ratio of 41.45, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PKI's ROE is +0.03%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, PKI is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for PKI.Check BNGOW's competition here